Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The study record for the phase 3 efprezimod alfa COVID-19 trial is displayed, including its eligibility criteria, treatment arms, outcomes, locations, and results-related information.
    Difference
    57%
    Check dated 2026-11-08T01:16:30.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T19:54:49.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces updates and FAQs about the transition from using “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-24T22:34:03.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The page no longer shows a 403 Forbidden message and instead displays the ClinicalTrials.gov site shell with a blank study-details area. The footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.6%
    Check dated 2026-10-17T22:41:07.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The page continues to show a 403 Forbidden error, and the displayed site revision changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T22:29:34.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record, replacing the previous content with a standard error screen and navigation. This makes the study details inaccessible on the page.
    Difference
    19%
    Check dated 2026-09-19T22:18:20.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.